🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

RecruitingNAAges 18 Years - 75 YearsAllJewish General Hospital
NCT05719415 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension Exclusion Criteria: * Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, * Presence of patent foramen ovale
💊

What it tests

  • Measurement of pulmonary functional capillary surface area
📍

Where

1 site
David Langleben
Montreal, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy